Auransa
Auransa is a clinical-stage AI-native biopharma discovering novel therapeutics for hard-to-treat diseases.
Founded
2014Auransa is a clinical-stage AI-native biopharma discovering novel therapeutics for hard-to-treat diseases.
Auransa takes a biology-first approach that starts from multi-omics profiles of diseased human tissue rather than from single targets or large random libraries. The SMarTR engine has been applied to more than five hundred thousand molecular profiles, letting the company test fewer than thirty prioritized compounds through deep functional validation.
This focused strategy has produced first-in-class clinical candidates such as AU-409, now in first-in-human trials for liver cancer. By predicting responder populations before clinical testing, the platform aims to raise the probability of success relative to conventional target-first discovery.
Source: auransa.com
Auransa operates in oncology drug development, where liver cancer and other hard-to-treat solid tumors continue to need safer and more effective therapies. Heart-safe chemotherapy alternatives such as AU-018 address the cardiac toxicity limits of widely used anthracycline regimens.
The company advances its pipeline through clinical testing and partnerships with pharmaceutical and academic collaborators, including its USC Norris clinical program, its research collaboration with POLARISqb on neglected womens diseases, and its licensing relationship with Lee Pharmaceutical in China. Continued progress depends on clinical readouts from the AU-409 Phase 1 trial and advancement of AU-018 toward regulatory filing.
Source:
Auransa is a clinical-stage AI-native biopharma company whose current flagship program is AU-409, a first-in-class investigational compound for liver cancer in Phase 1 testing. The program is run in collaboration with USC Norris and represents the most advanced output of the company discovery engine.
Behind the lead program, Auransa advances AU-018, a heart-safe chemotherapy candidate in IND-enabling development for anthracycline-type cancers. Both candidates originate from the company biology-first platform, which predicts disease-matched compounds from multi-omics human data.
Source: auransa.com